Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 CENCORA, INC. (Exact name of registrant as specified in its charter) Delaware 23-3079390 (S ...

Key Takeaways COR reported Q1 adjusted EPS of $4.08, beating estimates, while revenue rose 5.5% year over year.Cencora saw 5% U.S. segment revenue growth driven by GLP-1 and specialty drug demand.COR expanded adjusted gross margin by 37 bps and raised FY26 revenue growth guidance to 7-9%.Cencora, Inc. (COR) reported fiscal first-quarter 2026adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $4.07 by 0.2%. The bottom line also improved 9.4% year over year.GAAP EPS was $2.8 ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsBennett Murphy - SVP, Investor Relations and Enterprise ProductivityBob Motsch - President and CEOElizabeth Anderson - Senior Managing DirectorGeorge Hill - Managing DirectorGlen Santangelo - Managing DirectorJim Cleary - Executive VP and CFOLisa Gill - Managing DirectorMichael Cherny - Senior Managing DirectorSteven Collis - CEOConference Call ParticipantsAllen Lutz - Equity Research AnalystCharles Rhee - Managing Di ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsBennett Murphy - SVP, Investor Relations and Enterprise ProductivityBob Mauch - President and CEOElizabeth Anderson - Senior Managing DirectorGeorge Hill - Managing DirectorGlen Santangelo - Managing DirectorJim Cleary - Executive VP and CFOLisa Gill - Managing DirectorMichael Cherny - Senior Managing DirectorSteven Collis - CEOConference Call ParticipantsAllen Lutz - Equity Research AnalystCharles Rhee - Managing Dir ...

Cencora (NYSE:COR) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Speaker2It is now my pleasure to hand over to your host, Bennett Murphy, Senior Vice President of Investor Relations and Enterprise Productivity, to begin. Please go ahead.Speaker0Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2026 first quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob ...

Cencora (COR) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $4.07 per share. This compares to earnings of $3.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.35%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.79 per share when it actually produced earnings of $3.84, delivering a surprise of +1.32%.Over the last four quarters, ...

Cencora, Inc. First Quarter Fiscal 2026 Earnings Call February 4, 2026 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," ...

Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies. ...

Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FIRST QUARTER RESULTS Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaf irmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology CONSHOHOCKEN, PA, February 4, 2026 - Cencora, Inc. (NYSE: COR) reported that in its fiscal year 20 ...

Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.CENCORA, INC.FINANCIAL SUMMARY(in thousands, except per share data)(unaudited)Three MonthsEndedDecember 31, 2025% ofRevenueThree MonthsEndedDecember 31, 2024% ofRevenue%ChangeRevenue$85,932,01 ...